Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 235

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 235
---
 fractional SPAC Warrants shall be issued in connection with such separation such that if a holder of such SPAC Units would be entitled to receive a fractional SPAC Warrant upon such separation, the number of SPAC Warrants to be issued to such holder upon such separation will be rounded down to the nearest whole number of SPAC Warrants; •immediately following the separation of each SPAC Unit, each SPAC Class A Ordinary Share, issued and outstanding immediately prior to the Merger Effective Time shall be automatically surrendered, cancelled and cease to exist in exchange for the right to receive, upon delivery of the applicable Letter of Transmittal, one newly issued Company Share. Each SPAC Shareholder shall cease to have any other rights in and to such SPAC Ordinary Shares, except as expressly provided in the Business Combination Agreement; and •immediately following the separation of each SPAC Unit, each SPAC Warrant issued and outstanding immediately prior to the Merger Effective Time shall cease to be a warrant with respect to SPAC Ordinary Shares and be assumed by the Company and converted into a validly issued and fully paid warrant to purchase Company Shares. Each Company Warrant shall continue to have and be subject to substantially the same terms and conditions as were applicable to such SPAC Warrant immediately prior to the Merger Effective Time (including any repurchase rights and cashless exercise provisions) in accordance with the provisions of the SPAC Warrant Agreement and the Assignment, Assumption and Amendment Agreement. For more information on the Business Combination, see “ The Business Combination Agreement.” Basis of Presentation The adjustments presented on the pro forma combined financial statements have been identified and presented to provide an understanding of the Combined Company upon consummation of the Business Combination for illustrative purposes. The following unaudited pro forma combined consolidated financial information has been prepared in accordance with Article 11 of Regulation S -Xto depict the accounting for the transaction (the “Transaction Accounting Adjustments”). APx and OmnigenicsAI have elected not to present Management’s Adjustments and will only be presenting Transaction Accounting Adjustments in the following unaudited pro forma combined consolidated financial information. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, as it is a listed shell holding only cash raised as part of its original equity issuance. As a result, the portion of the Business Combination referring to the incorporation of APx does not qualify as a “business combination” within the meaning of IFRS3, Business Combinations; rather